A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data
<p>Abstract</p> <p>Background</p> <p>A key challenge in metabonomics is to uncover quantitative associations between multidimensional spectroscopic data and biochemical measures used for disease risk assessment and diagnostics. Here we focus on clinically relevant estim...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2007-05-01
|
Series: | BMC Bioinformatics |
id |
doaj-0bf76042db444c42b345dfb4070a2698 |
---|---|
record_format |
Article |
spelling |
doaj-0bf76042db444c42b345dfb4070a26982020-11-25T01:34:27ZengBMCBMC Bioinformatics1471-21052007-05-018Suppl 2S810.1186/1471-2105-8-S2-S8A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic dataKaski KimmoHannuksela Minna LSavolainen Markku JMäkelä Sanna MIngman PetriSoininen PasiMäkinen Ville-PetteriVehtari AkiAla-Korpela Mika<p>Abstract</p> <p>Background</p> <p>A key challenge in metabonomics is to uncover quantitative associations between multidimensional spectroscopic data and biochemical measures used for disease risk assessment and diagnostics. Here we focus on clinically relevant estimation of lipoprotein lipids by <sup>1</sup>H NMR spectroscopy of serum.</p> <p>Results</p> <p>A Bayesian methodology, with a biochemical motivation, is presented for a real <sup>1</sup>H NMR metabonomics data set of 75 serum samples. Lipoprotein lipid concentrations were independently obtained for these samples via ultracentrifugation and specific biochemical assays. The Bayesian models were constructed by Markov chain Monte Carlo (MCMC) and they showed remarkably good quantitative performance, the predictive R-values being 0.985 for the very low density lipoprotein triglycerides (VLDL-TG), 0.787 for the intermediate, 0.943 for the low, and 0.933 for the high density lipoprotein cholesterol (IDL-C, LDL-C and HDL-C, respectively). The modelling produced a kernel-based reformulation of the data, the parameters of which coincided with the well-known biochemical characteristics of the <sup>1</sup>H NMR spectra; particularly for VLDL-TG and HDL-C the Bayesian methodology was able to clearly identify the most characteristic resonances within the heavily overlapping information in the spectra. For IDL-C and LDL-C the resulting model kernels were more complex than those for VLDL-TG and HDL-C, probably reflecting the severe overlap of the IDL and LDL resonances in the <sup>1</sup>H NMR spectra.</p> <p>Conclusion</p> <p>The systematic use of Bayesian MCMC analysis is computationally demanding. Nevertheless, the combination of high-quality quantification and the biochemical rationale of the resulting models is expected to be useful in the field of metabonomics.</p> |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kaski Kimmo Hannuksela Minna L Savolainen Markku J Mäkelä Sanna M Ingman Petri Soininen Pasi Mäkinen Ville-Petteri Vehtari Aki Ala-Korpela Mika |
spellingShingle |
Kaski Kimmo Hannuksela Minna L Savolainen Markku J Mäkelä Sanna M Ingman Petri Soininen Pasi Mäkinen Ville-Petteri Vehtari Aki Ala-Korpela Mika A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data BMC Bioinformatics |
author_facet |
Kaski Kimmo Hannuksela Minna L Savolainen Markku J Mäkelä Sanna M Ingman Petri Soininen Pasi Mäkinen Ville-Petteri Vehtari Aki Ala-Korpela Mika |
author_sort |
Kaski Kimmo |
title |
A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data |
title_short |
A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data |
title_full |
A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data |
title_fullStr |
A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data |
title_full_unstemmed |
A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>H NMR metabonomic data |
title_sort |
novel bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in <sup>1</sup>h nmr metabonomic data |
publisher |
BMC |
series |
BMC Bioinformatics |
issn |
1471-2105 |
publishDate |
2007-05-01 |
description |
<p>Abstract</p> <p>Background</p> <p>A key challenge in metabonomics is to uncover quantitative associations between multidimensional spectroscopic data and biochemical measures used for disease risk assessment and diagnostics. Here we focus on clinically relevant estimation of lipoprotein lipids by <sup>1</sup>H NMR spectroscopy of serum.</p> <p>Results</p> <p>A Bayesian methodology, with a biochemical motivation, is presented for a real <sup>1</sup>H NMR metabonomics data set of 75 serum samples. Lipoprotein lipid concentrations were independently obtained for these samples via ultracentrifugation and specific biochemical assays. The Bayesian models were constructed by Markov chain Monte Carlo (MCMC) and they showed remarkably good quantitative performance, the predictive R-values being 0.985 for the very low density lipoprotein triglycerides (VLDL-TG), 0.787 for the intermediate, 0.943 for the low, and 0.933 for the high density lipoprotein cholesterol (IDL-C, LDL-C and HDL-C, respectively). The modelling produced a kernel-based reformulation of the data, the parameters of which coincided with the well-known biochemical characteristics of the <sup>1</sup>H NMR spectra; particularly for VLDL-TG and HDL-C the Bayesian methodology was able to clearly identify the most characteristic resonances within the heavily overlapping information in the spectra. For IDL-C and LDL-C the resulting model kernels were more complex than those for VLDL-TG and HDL-C, probably reflecting the severe overlap of the IDL and LDL resonances in the <sup>1</sup>H NMR spectra.</p> <p>Conclusion</p> <p>The systematic use of Bayesian MCMC analysis is computationally demanding. Nevertheless, the combination of high-quality quantification and the biochemical rationale of the resulting models is expected to be useful in the field of metabonomics.</p> |
work_keys_str_mv |
AT kaskikimmo anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT hannukselaminnal anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT savolainenmarkkuj anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT makelasannam anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT ingmanpetri anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT soininenpasi anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT makinenvillepetteri anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT vehtariaki anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT alakorpelamika anovelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT kaskikimmo novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT hannukselaminnal novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT savolainenmarkkuj novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT makelasannam novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT ingmanpetri novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT soininenpasi novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT makinenvillepetteri novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT vehtariaki novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata AT alakorpelamika novelbayesianapproachtoquantifyclinicalvariablesandtodeterminetheirspectroscopiccounterpartsinsup1suphnmrmetabonomicdata |
_version_ |
1725072010205200384 |